Malignancy contraindication for Regranex

Following a review by the European Medicines Agency, product information for the diabetic ulcer treatment becaplermin (Regranex) has been updated to include malignancy as a general contraindication.

The gel was previously contraindicated only in patients with skin cancer close to the application site.

In a retrospective study, patients who used three or more tubes of becaplermin had a 5.2 times greater risk of dying from cancer than matched controls, although their overall incidence of cancer was not increased.

View Regranex drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases